<S:Envelope xmlns:S="http://schemas.xmlsoap.org/soap/envelope/">
    <S:Body>
        <ns2:getStudyDetailsResponse xmlns:ns2="http://services.ctep.nci.nih.gov/">
            <StudyDetails>
                <ctcVersion>4.0</ctcVersion>
                <currentStatus>Active</currentStatus>
                <currentStatusDate>2009-05-15</currentStatusDate>
                <localDocumentNumber>CALGB-40603</localDocumentNumber>
                <monitoringMethod>CDUS - Complete</monitoringMethod>
                <nciDocumentNum>CALGB-40603</nciDocumentNum>
                <participantionType>Group</participantionType>
                <phase>II</phase>
                <primaryStudyType>Treatment</primaryStudyType>
                <sponsorOrganization>CTEP</sponsorOrganization>
                <studyAgents>
                    <studyAgent lead="Yes" updatedDate="08-04-2010 10:58:19" createdDate="03-03-2008 15:56:57">
                        <agent>
                            <nscNumber>704865</nscNumber>
                            <agentName>Bevacizumab (rhuMAb VEGF)</agentName>
                            <agentStatus>Active</agentStatus>
                            <inds/>
                        </agent>
                        <commercialInvestigational>Investigational</commercialInvestigational>
                    </studyAgent>
                    <studyAgent lead="No" updatedDate="03-11-2009 13:15:30" createdDate="03-03-2008 15:58:49">
                        <agent>
                            <nscNumber>673089</nscNumber>
                            <agentName>Paclitaxel (Taxol)</agentName>
                            <agentStatus>Active</agentStatus>
                            <inds/>
                        </agent>
                        <commercialInvestigational>Commercial</commercialInvestigational>
                    </studyAgent>
                    <studyAgent lead="No" updatedDate="03-11-2009 14:52:03" createdDate="03-03-2008 16:00:45">
                        <agent>
                            <nscNumber>241240</nscNumber>
                            <agentName>CARBOplatin</agentName>
                            <agentStatus>Active</agentStatus>
                            <inds/>
                        </agent>
                        <commercialInvestigational>Commercial</commercialInvestigational>
                    </studyAgent>
                    <studyAgent lead="No" updatedDate="03-11-2009 13:15:30" createdDate="03-03-2008 16:01:13">
                        <agent>
                            <nscNumber>123127</nscNumber>
                            <agentName>Doxorubicin hydrochloride</agentName>
                            <agentStatus>Active</agentStatus>
                            <inds/>
                        </agent>
                        <commercialInvestigational>Commercial</commercialInvestigational>
                    </studyAgent>
                    <studyAgent lead="No" updatedDate="03-11-2009 13:15:30" createdDate="03-03-2008 16:01:44">
                        <agent>
                            <nscNumber>26271</nscNumber>
                            <agentName>Cyclophosphamide</agentName>
                            <agentStatus>Active</agentStatus>
                            <inds/>
                        </agent>
                        <commercialInvestigational>Commercial</commercialInvestigational>
                    </studyAgent>
                    <studyAgent lead="No" updatedDate="" createdDate="03-12-2009 16:05:30">
                        <agent>
                            <nscNumber>614629</nscNumber>
                            <agentName>G-CSF (filgrastim, Amgen)</agentName>
                            <agentStatus>Active</agentStatus>
                            <inds/>
                        </agent>
                        <commercialInvestigational>Commercial</commercialInvestigational>
                    </studyAgent>
                    <studyAgent lead="No" updatedDate="" createdDate="03-12-2009 16:05:30">
                        <agent>
                            <nscNumber>725961</nscNumber>
                            <agentName>Pegfilgrastim (Neulasta)</agentName>
                            <agentStatus>Active</agentStatus>
                            <inds/>
                        </agent>
                        <commercialInvestigational>Commercial</commercialInvestigational>
                    </studyAgent>
                    <studyAgent lead="No" updatedDate="" createdDate="03-12-2009 16:05:30">
                        <agent>
                            <nscNumber>34521</nscNumber>
                            <agentName>Dexamethasone</agentName>
                            <agentStatus>Active</agentStatus>
                            <inds/>
                        </agent>
                        <commercialInvestigational>Commercial</commercialInvestigational>
                    </studyAgent>
                    <studyAgent lead="No" updatedDate="" createdDate="03-12-2009 16:09:20">
                        <agent>
                            <nscNumber>613795</nscNumber>
                            <agentName>GM-CSF (sargramostim, Leukine)</agentName>
                            <agentStatus>Active</agentStatus>
                            <inds/>
                        </agent>
                        <commercialInvestigational>Commercial</commercialInvestigational>
                    </studyAgent>
                </studyAgents>
                <studyDevices/>
                <studyDiseases>
                    <studyDisease lead="Yes" updatedDate="" createdDate="03-11-2009 14:37:55">
                        <diseaseName>Invasive breast carcinoma</diseaseName>
                        <reportingMedDRA>10006190</reportingMedDRA>
                    </studyDisease>
                </studyDiseases>
                <studyOrganizations>
                    <studyOrganization role="Document to Lead Organization" updatedDate="04-15-2010 11:29:16" createdDate="03-03-2008 15:27:35">
                        <localDocumentNumber>CALGB-40603</localDocumentNumber>
                        <organization>
                            <ctepId>CALGB</ctepId>
                            <organizationName>Cancer and Leukemia Group B</organizationName>
                            <organizationType>CGP</organizationType>
                        </organization>
                        <status>Active</status>
                        <statusDate>03-03-2008 00:00:00</statusDate>
                        <principalInvestigator ctepInvestigatorId="1777">
                            <firstname>William</firstname>
                            <middlename>Marshall</middlename>
                            <lastname>Sikov</lastname>
                            <email>gov.nih.nci.ctep.domain.ContactDetail@1a5c08fe</email>
                            <investigatorStatus>Active</investigatorStatus>
                        </principalInvestigator>
                    </studyOrganization>
                    <studyOrganization role="Document to Participant Organization" updatedDate="04-15-2010 11:29:14" createdDate="03-07-2008 10:53:20">
                        <organization>
                            <ctepId>CTSU</ctepId>
                            <organizationName>Cancer Trials Support Unit</organizationName>
                            <organizationType>CGP</organizationType>
                        </organization>
                        <status>Active</status>
                        <statusDate>04-15-2010 00:00:00</statusDate>
                    </studyOrganization>
                </studyOrganizations>
                <studyTherapies>
                    <therapy updatedDate="11-30-2009 12:07:12" createdDate="03-03-2008 16:06:17">
                        <ctepName>Drug and/or Immunotherapy</ctepName>
                        <medDRACode>90003006</medDRACode>
                    </therapy>
                    <therapy preferredTerm="Surgery" updatedDate="03-11-2009 15:47:14" createdDate="03-03-2008 16:13:52">
                        <ctepName>Surgery</ctepName>
                        <medDRACode>10042609</medDRACode>
                    </therapy>
                    <therapy preferredTerm="Radiation Therapy" updatedDate="03-11-2009 15:47:14" createdDate="03-03-2008 16:13:52">
                        <ctepName>Radiation Therapy</ctepName>
                        <medDRACode>10037770</medDRACode>
                    </therapy>
                </studyTherapies>
                <studyTreatmentAssignments>
                    <studyTreatmentAssignment updatedDate="02-10-2009 16:03:32" createdDate="03-03-2008 16:40:26">
                        <tacDbId>16164</tacDbId>
                        <code>ARM1</code>
                        <description>Cycle = 19 weeks:
                            Paclitaxel:  80 mg/m2 IV over 1 hr on day 1 of wks 1-12
                            Doxorubicin:  60 mg/m2/ IV over 5-10 min on day 1 of wks 13, 15, 17 and 19
                            Cyclophosphamide:  600 mg/m2 IV over 5-30 min on day 1 of wks 13, 15, 17 and 19</description>
                        <status>Active</status>
                    </studyTreatmentAssignment>
                    <studyTreatmentAssignment updatedDate="02-10-2009 16:06:50" createdDate="03-03-2008 16:40:26">
                        <tacDbId>16165</tacDbId>
                        <code>ARM2</code>
                        <description>Cycle = 19 weeks:
                            Paclitaxel:  80 mg/m2 IV over 1 hr on day 1 of  wks 1-12
                            Bevacizumab:  10 mg/kg over 30-90 min on day 1 of wks 1, 3, 5, 7, 9, 11, 13, 15 and 17
                            Doxorubicin:  60 mg/m2/ IV over 5-10 min on day 1 of wks 13, 15, 17 and 19
                            Cyclophosphamide:  600 mg/m2 IV over 5-30 min on day 1 of wks 13, 15, 17 and 19</description>
                        <status>Active</status>
                    </studyTreatmentAssignment>
                    <studyTreatmentAssignment updatedDate="02-10-2009 16:09:35" createdDate="03-03-2008 16:52:52">
                        <tacDbId>16166</tacDbId>
                        <code>ARM3</code>
                        <description>Cycle = 19 weeks:
                            Paclitaxel:  80 mg/m2 IV over 1 hr on day 1 of wks 1-12
                            Carboplatin:  AUC 6 IV over 30 min on day 1 of wks 1, 4, 7 and 10
                            Doxorubicin:  60 mg/m2/ IV over 5-10 min on day 1 of wks 13, 15, 17 and 19
                            Cyclophosphamide:  600 mg/m2 IV over 5-30 min on day 1 of wks 13, 15, 17 and 19</description>
                        <status>Active</status>
                    </studyTreatmentAssignment>
                    <studyTreatmentAssignment updatedDate="02-10-2009 16:12:39" createdDate="03-03-2008 16:54:23">
                        <tacDbId>16167</tacDbId>
                        <code>ARM4</code>
                        <description>Cycle = 19 weeks:
                            Paclitaxel:  80 mg/m2 IV over 1 hr on day 1 of wks 1-12
                            Carboplatin:  AUC 6 IV over 30 min on day 1 of wks 1, 4, 7 and 10
                            Bevacizumab:  10 mg/kg over 30-90 min on day 1 of wks 1, 3, 5, 7, 9, 11, 13, 15 and 17
                            Doxorubicin:  60 mg/m2/ IV over 5-10 min on day 1 of  wks 13, 15, 17 and 19
                            Cyclophosphamide:  600 mg/m2 IV over 5-30 min on day 1 of wks 13, 15, 17 and 19</description>
                        <status>Active</status>
                    </studyTreatmentAssignment>
                    <studyTreatmentAssignment updatedDate="02-06-2009 15:49:39" createdDate="03-04-2008 12:55:16">
                        <tacDbId>16170</tacDbId>
                        <code>SURG</code>
                        <description>Surgery</description>
                        <status>Active</status>
                    </studyTreatmentAssignment>
                    <studyTreatmentAssignment updatedDate="02-23-2009 13:00:42" createdDate="02-23-2009 12:55:11">
                        <tacDbId>16742</tacDbId>
                        <code>RADIATION</code>
                        <description>Ipsilateral remaining breast or chest wall RT:  5000 cGy in 2 Gy fractions or  5040 cGy in 1.8 Gy fractions
                            Intact breast RT:  1000-1600 cGy in 180-200 Gy fractions
                            Supraclavicular field RT:  4500-5040 cGy in 1.8-2 Gy fractions</description>
                        <status>Active</status>
                    </studyTreatmentAssignment>
                </studyTreatmentAssignments>
                <title>Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer</title>
            </StudyDetails>
        </ns2:getStudyDetailsResponse>
    </S:Body>
</S:Envelope>